| |
|
|
Daewoong Pharmaceutical (069620) |
|
|
STOCK |
|
|
| Address |
223-23,SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI |
| Home Page |
www.daewoong.co.kr
|
| Established |
2002.10. 1 |
Tel |
031-741-7700 |
| Listed |
2002.11. 1 |
IR |
02-550-8138 |
| Common shares O/S |
10,152,219 |
President |
Yun,Jae Seung/Lee,Jong Uk |
| Preferred shares O/S |
|
No.of Employees |
1,193(2008. 3) |
| Its sales increased on rising demand for Ursa sc and CoQ10 and other products such as allmetech and gasmotin. Its profitability improved on increased sales of its mainstay product, Olmesartan medoxomil. Its market dominance solidified on success of CoQ10 and obesity-related medicine. |
| Despite government policy to lower medicine prices, its sales of new drugs such as Alvis are expected to increase. Its profit is expected to increase on its efforts to roll out new drugs and functional medicines. Its sales are forecast to increase on its continued efforts to produce new drugs. |
|
  |
(date: 2007.12, unit : %) |
| Name |
Daewoong |
Dae Woong Foundation |
Yoon Yeonghwan |
| Portion |
40.0 |
5.0 |
3.4 |
|
 |
(unit : %) |
| Sales |
Ursa sc |
11.9 |
Cost |
Raw Materials |
|
| Gasmotin tab |
8.7 |
Labors |
|
|
|
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
02.11 |
- |
- |
- |
- |
| Type |
LI |
- |
- |
- |
- |
| Amount |
246.96 |
- |
- |
- |
- |
|
|
|
|
